MCID: CND004
MIFTS: 61

Candidiasis

Categories: Rare diseases, Infectious diseases, Genetic diseases, Immune diseases, Blood diseases, Skin diseases

Aliases & Classifications for Candidiasis

MalaCards integrated aliases for Candidiasis:

Name: Candidiasis 12 72 51 3 41 14 69
Systemic Candidiasis 12 49 69
Invasive Candidiasis 49 3 69
Disseminated Candidiasis 12 51
Systemic Candida Infections 49

Classifications:



External Ids:

Disease Ontology 12 DOID:1508
ICD10 32 B37 B37.9
ICD9CM 34 112 112.9
MeSH 41 D002177
NCIt 46 C26711

Summaries for Candidiasis

NIH Rare Diseases : 49 Systemic candidiasis includes a spectrum of yeast infections caused by different species (types) of Candida. It is a serious infection that can affect the blood, heart, brain, eyes, bones, or other parts of the body. Although there are over 200 species of Candida, five different species of Candida cause 90% of systemic candidiasis. The most common form of this invasive yeast infection is when Candida enters the bloodstream (candidemia). Signs of candidemia include fever and chills that do not improve with antibiotics. Symptoms of other types of systemic candidiasis depend on the organ or system which is infected. Systemic candidiasis is the most common fungal infection among hosptilized people in high-income countries, including the United States. Diagnosis can be difficult, especially when the Candida is not found in the bloodstream. Treatment usually includes consists of oral or intravenous (IV) antifungal medications.  Last updated: 12/15/2016

MalaCards based summary : Candidiasis, also known as systemic candidiasis, is related to candidiasis, familial, 2 and familial candidiasis. An important gene associated with Candidiasis is AIRE (Autoimmune Regulator), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Fluconazole and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and skin, and related phenotypes are hematopoietic system and immune system

CDC : 3 Photomicrograph of the fungus Candida albicans

Disease Ontology : 12 An opportunistic mycosis that involves fungal infection of the mouth, throat, skin, scalp, vagina, fingers, nails, bronchi, lungs, heart and brain by Candida species, of which Candida albicans is the most common. Systemic Candida infections are usually confined to severely immunocompromised persons.

Wikipedia : 72 Candidiasis is a fungal infection due to any type of Candida (a type of yeast). When it affects the... more...

Related Diseases for Candidiasis

Diseases in the Candidiasis family:

Candidiasis, Familial, 1 Candidiasis, Familial, 2
Candidiasis, Familial, 3 Candidiasis, Familial, 4
Candidiasis, Familial, 6 Candidiasis, Familial, 8
Candidiasis, Familial, 9 Familial Candidiasis

Diseases related to Candidiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 321)
# Related Disease Score Top Affiliating Genes
1 candidiasis, familial, 2 34.3 CARD9 CLEC7A
2 familial candidiasis 34.1 CANDF1 CANDN1 CLEC7A
3 oral candidiasis 34.0 DEFB4A HTN3 SKAP2
4 vulvovaginal candidiasis 33.7 CD79A CLEC7A DEFB4A IFNG
5 chronic mucocutaneous candidiasis 31.4 AIRE CLEC7A HSP90AA1 IFNG IL10 IL17A
6 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.9 AIRE IFNG IL10 IL17A
7 invasive aspergillosis 30.2 CD79A CLEC7A IFNG
8 aspergillosis 30.1 CD79A CLEC7A IFNG IL10
9 acquired immunodeficiency syndrome 30.1 CD79A IFNG IL10
10 coccidioidomycosis 30.0 CARD9 CLEC7A STAT1
11 candida glabrata 29.9 APCS HTN3 IFNG SKAP2
12 hematopoietic stem cell transplantation 29.9 CLEC7A IFNG IL10
13 myasthenia gravis 29.8 AIRE IFNG IL10
14 trichosporonosis 29.8 IFNG IL17A
15 mycobacterium tuberculosis 1 29.7 IFNG IL10 IL17A
16 immune suppression 29.7 IFNG IL10
17 sporotrichosis 29.5 CD79A IFNG IL10
18 uveitis 29.4 IFNG IL10 IL17A
19 toxoplasmosis 29.4 CD79A IFNG IL10
20 psoriasis 29.3 DEFB4A IFNG IL10 IL17A TRAF3IP2
21 autoimmune disease 28.9 AIRE CD79A IFNG IL10 IL17A
22 human immunodeficiency virus type 1 28.5 APCS IFNG IL10 STAT1
23 neonatal candidiasis 12.3
24 esophageal candidiasis 12.3
25 candidiasis, familial, 4 12.3
26 cutaneous candidiasis 12.2
27 candidiasis, familial, 6 12.2
28 candidiasis, familial, 1 12.2
29 candidiasis, familial, 8 12.2
30 candidiasis, familial, 9 12.1
31 autoimmune polyendocrine syndrome, type i, with or without reversible metaphyseal dysplasia 12.0
32 candidiasis, familial, 3 11.9
33 candidal paronychia 11.7
34 immunodeficiency 51 11.7
35 immunodeficiency 31c 11.7
36 autoimmune polyendocrine syndrome type 1 11.7
37 vaginitis 11.3
38 myeloperoxidase deficiency 11.1
39 median rhomboid glossitis 11.1
40 biotinidase deficiency 11.1
41 immunodeficiency 32b 10.9
42 immunodeficiency 42 10.9
43 vulvovaginitis 10.8
44 reticular dysgenesis 10.8
45 autoimmune polyendocrine syndrome, type ii 10.8
46 severe combined immunodeficiency, x-linked 10.8
47 t-cell receptor-alpha/beta deficiency 10.8
48 immunodeficiency 26 with or without neurologic abnormalities 10.8
49 immunodeficiency with thymoma 10.8
50 esophagitis 10.6

Comorbidity relations with Candidiasis via Phenotypic Disease Network (PDN): (show all 13)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Chronic Kidney Failure
Decubitus Ulcer Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hydronephrosis Intestinal Obstruction
Paralytic Ileus Protein-Energy Malnutrition
Respiratory Failure

Graphical network of the top 20 diseases related to Candidiasis:



Diseases related to Candidiasis

Symptoms & Phenotypes for Candidiasis

MGI Mouse Phenotypes related to Candidiasis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.18 CARD9 CD79A IL17F CLEC7A IL17RA IFNG
2 immune system MP:0005387 10.13 CD79A IL17F CLEC7A IL17RA HSP90AA1 IFNG
3 homeostasis/metabolism MP:0005376 10.1 CARD9 IL17A CD79A CLEC7A IL17RA IFNG
4 digestive/alimentary MP:0005381 10.01 IL17A IL17F CLEC7A IFNG AIRE IL10
5 no phenotypic analysis MP:0003012 9.7 IL17A CD79A IL17RA IFNG AIRE IL10
6 normal MP:0002873 9.56 CD79A IL17F IFNG AIRE IL10 APCS
7 respiratory system MP:0005388 9.23 IL17A IL17F CLEC7A IL17RA IFNG AIRE

Drugs & Therapeutics for Candidiasis

Drugs for Candidiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 207)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluconazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 86386-73-4 3365
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 22916-47-8 4189
3
Anidulafungin Approved, Investigational Phase 4,Phase 3,Phase 2 166663-25-8 166548
4
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2 1397-89-3 5280965 14956
5
Micafungin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 235114-32-6 477468 3081921
6
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Early Phase 1 18323-44-9 29029
7
Clotrimazole Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 23593-75-1 2812
8
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 657311 5754
9
Dequalinium Approved, Investigational Phase 4 6707-58-0
10
Caspofungin Approved Phase 4,Phase 3,Phase 2 162808-62-0, 179463-17-3 2826718 468682
11
Voriconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 137234-62-9 71616
12
Terconazole Approved Phase 4,Early Phase 1 67915-31-5 441383
13
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
14 Racepinephrine Approved Phase 4 329-65-7
15
Nystatin Approved, Vet_approved Phase 4,Phase 3,Phase 2 1400-61-9 11953884
16
Metronidazole Approved Phase 4,Phase 3,Phase 2,Early Phase 1 443-48-1 4173
17
Itraconazole Approved, Investigational Phase 4,Phase 3,Phase 1 84625-61-6 55283
18
Ephedrine Approved Phase 4 299-42-3 9294
19
Pseudoephedrine Approved Phase 4 90-82-4 7028
20
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3 128794-94-5 5281078
21
Mycophenolic acid Approved Phase 4,Phase 3 24280-93-1 446541
22
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
23
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
24 Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4
25
Butyric Acid Experimental, Investigational Phase 4 107-92-6 264
26 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
27 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
28 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
29 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
30 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
31 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
33 Steroid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Echinocandins Phase 4,Phase 2,Phase 3,Phase 1
35 Adrenergic Agents Phase 4,Phase 3,Phase 2
36 Adrenergic Agonists Phase 4,Phase 3,Phase 2
37 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 3,Phase 2
38 Adrenergic beta-Agonists Phase 4,Phase 3,Phase 2
39 Anti-Allergic Agents Phase 4,Phase 3,Phase 2
40 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2
41 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
42 Autonomic Agents Phase 4,Phase 3,Phase 2
43 Bronchodilator Agents Phase 4,Phase 3,Phase 2
44 Dermatologic Agents Phase 4,Phase 3,Phase 2
45
Fluticasone Phase 4,Phase 3,Phase 2 80474-14-2, 90566-53-3 22833648 62924
46 Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Phase 4,Phase 3
47 glucocorticoids Phase 4,Phase 3,Phase 2
48 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
49 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 291)

# Name Status NCT ID Phase Drugs
1 Clinical Significance of Smear or Culture Positive for Candida Spp. From Sputum Three Times a Week Unknown status NCT00537888 Phase 4 fluconazole
2 A Pilot Study for the Use of Biomarkers and Early Treatment of Invasive Candidiasis in Intensive Care Unit (ICU) Patients Unknown status NCT01734525 Phase 4 Anidulafungin
3 Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
4 Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis Completed NCT02248506 Phase 4
5 An Efficacy and Safety Study of Miconazole and Hydrocortisone Cream in the Treatment of Vulvar Candidiasis Completed NCT01769339 Phase 4 Miconazole plus Hydrocortisone
6 Single Dose Versus Two Weeks Course of Fluconazole in the Treatment of Oropharyngeal Candidiasis in HIV Infected Individuals in Tanzania Completed NCT00553137 Phase 4 fluconazole;fluconazole
7 Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4 Fluomizin vaginal tablets;Canesten vaginal tablets
8 Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU) Completed NCT00520234 Phase 4 Caspofungin;Normal Saline
9 Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
10 Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis Completed NCT00496197 Phase 4 Eraxis (anidulafungin);Diflucan (fluconazole);Vfend (voriconazole)
11 This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis Completed NCT00548262 Phase 4 Anidulafungin;Voriconazole
12 CRITIC - Treatment of Candidemia and Invasive Candidiasis Completed NCT00670657 Phase 4 AmBisome
13 Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis Completed NCT02180100 Phase 4 Terconazole Vaginal Suppository;Fluconazole
14 A Study to Compare the Use of Fluconazole as Continuous Therapy Versus Periodic Therapy in HIV-Positive Patients With Recurrent Thrush Completed NCT00000951 Phase 4 Fluconazole
15 Optimized Radiological Diagnosis of Hepatic Candidiasis During the Treatment of Acute Leukemias Completed NCT01207843 Phase 4
16 Fluconazole Prophylaxis of Thrush in AIDS Completed NCT00001542 Phase 4 fluconazole
17 Optimal Dosage of Caspofungin in Critically Ill Patients Completed NCT01994096 Phase 4 Caspofungin
18 Pharmacokinetics of Micafungin in Patients of Intensive Care Units Completed NCT02164890 Phase 4
19 Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection Completed NCT00388167 Phase 4 Caspofungin
20 Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants Completed NCT00702507 Phase 4 0.25 % Miconazole Nitrate Ointment
21 Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants Completed NCT00001107 Phase 4 Fluconazole;AmBisome
22 Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina Completed NCT00194324 Phase 4 Miconazole nitrate
23 Effectiveness of Hygiene Solutions on Denture Biofilm Completed NCT02407834 Phase 4
24 A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections Completed NCT00647907 Phase 4 Voriconazole
25 Antifungal Prophylaxis in Intensive Care Unit (ICU) Patients Completed NCT01495039 Phase 4 Nystatin
26 Micafungin Pharmacokinetics in Obese Patients Completed NCT03102658 Phase 4 Micafungin
27 Anidulafungin Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ADOPT) Completed NCT02021123 Phase 4 Anidulafungin 100mg single dose iv
28 Pharmacokinetics of Micafungin During Continuous Venovenous Hemofiltration Completed NCT02651038 Phase 4 Micafungin
29 Lactoserum (Dermacyd Femina®) and Prevention of Recurrence of Bacterial Vaginosis Completed NCT00556179 Phase 4 Lactoserum (Dermacyd Femina®)
30 Comparison of Two Topical Formulations Containing Clindamycin and Clotrimazole in Patients With Vaginal Infections Completed NCT01697826 Phase 4 ClinSupV3 -soft gelatin capsule;ClinSupV3ER- Extended release tablet
31 Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins Completed NCT00839540 Phase 4 micafungin;Micafungin;Caspofungin
32 A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects Completed NCT00940017 Phase 4 anidulafungin and voriconazole
33 Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections Recruiting NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
34 Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins Terminated NCT01213823 Phase 4
35 A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia Terminated NCT01982071 Phase 4 Micafungin
36 Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Terminated NCT02646800 Phase 4 Micafungin
37 Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children Terminated NCT01646580 Phase 4 ciclopirox
38 Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients Terminated NCT01282879 Phase 4 Itraconazole
39 Fluconazole Versus Micafungin for Candida Bloodstream Infection in Non-Neutropenic Patients Withdrawn NCT00304772 Phase 4 Fluconazole;Micafungin
40 RCT of Postoperative Infections Following Caesarean Section Infections Following Caesarean Section Withdrawn NCT02009098 Phase 4 Cefuroxime
41 Fluconazole Versus Micafungin in Neonates With Candidiasis Unknown status NCT02145832 Phase 2, Phase 3 Fluconazole;Micafungin
42 Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis Unknown status NCT00889356 Phase 3 Clindamycin 100mg and Ketoconazole 400mg;Tetracycline 100mg and Amphotericin B 50mg
43 Dysbiosis in Localized Provoked Vulvodynia (LPV) Unknown status NCT02393911 Phase 3
44 Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia Unknown status NCT01270490 Phase 3 Interferon-gamma, Recombinant
45 Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight Completed NCT00734539 Phase 3 fluconazole;placebo
46 A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis Completed NCT00128323 Phase 3 Gentian violet 1% solution;Gentian violet 0.00165% solution;Nystatin solution
47 Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis Completed NCT00666185 Phase 3 Micafungin;Fluconazole
48 Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis Completed NCT00665639 Phase 3 micafungin;caspofungin
49 Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis Completed NCT02251093 Phase 3 Lcr Regenerans;Placebo
50 The Study Of Fluconazole For Vulvovaginal Candidiasis Completed NCT01806623 Phase 3 Fluconazole

Search NIH Clinical Center for Candidiasis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: candidiasis

Genetic Tests for Candidiasis

Anatomical Context for Candidiasis

MalaCards organs/tissues related to Candidiasis:

38
Brain, Heart, Skin, Tongue, Colon, Lung, Bone

Publications for Candidiasis

Articles related to Candidiasis:

(show top 50) (show all 1915)
# Title Authors Year
1
Chronic disseminated candidiasis and acute leukemia: Impact on survival and hematopoietic stem cell transplantation agenda. ( 29307444 )
2018
2
Prevalence and association of oral candidiasis with dysphagia in individuals with acquired brain injury. ( 29182379 )
2018
3
Nanolipid Gel of an Antimycotic Drug for Treating Vulvovaginal Candidiasis-Development and Evaluation. ( 29340981 )
2018
4
Caspofungin resistant disseminated candidiasis in a 7-year-old girl with T cell lymphoma: a case report. ( 29441283 )
2018
5
Lactobacillus rhamnosus intake can prevent the development of Candidiasis. ( 29372447 )
2018
6
Antifungal activity of clinical Lactobacillus strains against Candida albicans biofilms: identification of potential probiotic candidates to prevent oral candidiasis. ( 29380647 )
2018
7
Patient Susceptibility to Candidiasis-A Potential for Adjunctive Immunotherapy. ( 29371502 )
2018
8
A Retrospective Assessment of Four Antigen Assays for the Detection of Invasive Candidiasis Among High-Risk Hospitalized Patients. ( 29356937 )
2018
9
Proanthocyanidin polymeric tannins from Stryphnodendron adstringens are effective against Candida spp. isolates and for vaginal candidiasis treatment. ( 29325916 )
2018
10
Computer-aided diagnosis software for vulvovaginal candidiasis detection from Pap smear images. ( 28987021 )
2018
11
Experimental in Vivo Models of Candidiasis. ( 29415485 )
2018
12
Antifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis. ( 29369937 )
2018
13
Usefulness of A9-D-glucan for diagnosis and follow-up of invasive candidiasis in onco-haematological patients. ( 29432826 )
2018
14
Surface-modified mucoadhesive microgels as a controlled release system for miconazole nitrate to improve localized treatment of vulvovaginal candidiasis. ( 28986195 )
2018
15
Saccharomyces cerevisiae-based probiotic as novel anti-fungal and anti-inflammatory agent for therapy of vaginal candidiasis. ( 29380641 )
2018
16
Development, characterization, and in vitro-in vivo evaluation of polymeric nanoparticles containing miconazole and farnesol for treatment of vulvovaginal candidiasis. ( 29361177 )
2018
17
Tetraglochin cristatum (Britton) Roth: a medicinal plant from the Argentinean highlands with potential use in vaginal candidiasis. ( 29307753 )
2018
18
Novel Mechanism behind the Immunopathogenesis of Vulvovaginal Candidiasis: "Neutrophil Anergy". ( 29203543 )
2018
19
New evidence on oral L. plantarum P17630 product in women with history of recurrent vulvovaginal candidiasis (RVVC): a randomized double-blind placebo-controlled study. ( 29364495 )
2018
20
Diagnosing Invasive Candidiasis. ( 29444828 )
2018
21
Candida Endophthalmitis After Descemet Stripping Automated Endothelial Keratoplasty With Grafts From Both Eyes of a Donor With Possible Systemic Candidiasis. ( 29303885 )
2018
22
<i>In Vivo</i> Pharmacokinetics and Pharmacodynamics of APX001 against<i>Candida s</i>pp. in a Neutropenic Disseminated Candidiasis Mouse Model. ( 29378706 )
2018
23
Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia. ( 29364548 )
2018
24
Clinical characteristics of the first cases of invasive candidiasis in China due to pan-echinocandin-resistant<i>Candida tropicalis</i>and<i>Candida glabrata</i>isolates with delineation of their resistance mechanisms. ( 29416360 )
2018
25
Effectiveness of Ageratina pichinchensis Extract in Patients with Vulvovaginal Candidiasis. A Randomized, Double-Blind, and Controlled Pilot Study. ( 28299831 )
2017
26
A meta-analysis of randomized trials assessing the effects of probiotic preparations on oral candidiasis in the elderly. ( 28783552 )
2017
27
New and recurrent STAT1 mutations in seven Chinese patients with chronic mucocutaneous candidiasis. ( 27808400 )
2017
28
Quantity of Candida Colonies in Saliva: a8"A Diagnostic Evaluation for Oral Candidiasis. ( 28232964 )
2017
29
Characterization of virulence factors of vaginal and anal isolates of Candida albicans sequentially obtained from patients with vulvovaginal candidiasis in north-east Brazil. ( 28844452 )
2017
30
Molecular Identification and Antifungal Susceptibility Pattern of Non-albicans Candida Species Isolated from Vulvovaginal Candidiasis ( 28688376 )
2017
31
Acute disseminated candidiasis with skin lesions: a systematic review. ( 28847765 )
2017
32
"Rhetoric to Reality"- Efficacy of Punica Granatum Peel Extract on OralA Candidiasis: An in vitro Study. ( 28274059 )
2017
33
TNF as marker of oral candidiasis, HSV infection, and mucositis onset during chemotherapy in leukemia patients. ( 28403570 )
2017
34
Invasive candidiasis: future directions in non-culture based diagnosis. ( 28829207 )
2017
35
Fungal Profile of Vulvovaginal Candidiasis in a Tertiary Care Hospital. ( 28511380 )
2017
36
Volatile organic compounds in the breath of oral candidiasis patients: a pilot study. ( 28601915 )
2017
37
Chronic Mucocutaneous Candidiasis. ( 28065688 )
2017
38
Prevalence of Candida albicans, Candida dubliniensis and Candida africana in pregnant women suffering from vulvovaginal candidiasis in Argentina. ( 28385421 )
2017
39
Case of recurrent severe cellulitis and cutaneous candidiasis during psoriasis treatment with ustekinumab. ( 28432713 )
2017
40
Induction of Severe Chronic Hyperplastic Candidiasis in Rat by Opportunistic Infection of C. albicans through Combination of Diabetes and Intermittent Prednisolone Administration. ( 28830301 )
2017
41
Oral health: Asthma and oral candidiasis. ( 29123274 )
2017
42
Novel solidified reverse micellar solution-based mucoadhesive nano lipid gels encapsulating miconazole nitrate-loaded nanoparticles for improved treatment of oropharyngeal candidiasis. ( 28877639 )
2017
43
A Novel Heterozygous Mutation in the STAT1 SH2 Domain Causes Chronic Mucocutaneous Candidiasis, Atypically Diverse Infections, Autoimmunity, and Impaired Cytokine Regulation. ( 28348565 )
2017
44
Oral candidiasis: A retrospective study of 276 Brazilian patients. ( 29391707 )
2017
45
Oropharyngeal candidiasis prevalence among HIV-infected patients at the teaching hospital of Treichville (Abidjan, CA'te d'Ivoire). ( 28867257 )
2017
46
Probiotics for vulvovaginal candidiasis in non-pregnant women. ( 29168557 )
2017
47
Vegetating Candidiasis: A Mimicker of Squamous Cell Carcinoma in Keratitis Ichthyosis Deafness Syndrome. ( 28111777 )
2017
48
Emergence of Candida glabrata in vulvovaginal candidiasis should be attributed to selective pressure or virulence ability? ( 28730269 )
2017
49
Candidiasis and the impact of flow cytometry on antifungal drug discovery. ( 28876963 )
2017
50
Disseminated Tuberculosis and Chronic Mucocutaneous Candidiasis in a Patient with a Gain-of-Function Mutation in Signal Transduction and Activator of Transcription 1. ( 29270166 )
2017

Variations for Candidiasis

Expression for Candidiasis

Search GEO for disease gene expression data for Candidiasis.

Pathways for Candidiasis

Pathways related to Candidiasis according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 CARD9 CD79A CLEC7A DEFB4A HSP90AA1 HTN3
2
Show member pathways
13.21 HSP90AA1 IFNG IL10 IL17A IL17F IL17RA
3
Show member pathways
12.7 HSP90AA1 IFNG IL10 IL17A STAT1
4
Show member pathways
12.44 IFNG IL10 IL17A IL17F STAT1
5
Show member pathways
12.38 HSP90AA1 IFNG IL10 IL17A IL17F STAT1
6 12.31 CARD9 CD79A IFNG IL10 IL17A STAT1
7 12.05 CARD9 CLEC7A IFNG IL10 STAT1
8
Show member pathways
11.99 IFNG IL10 IL17A STAT1
9
Show member pathways
11.77 IFNG IL10 IL17A STAT1
10 11.71 HSP90AA1 IL10 IL17A IL17F STAT1
11 11.64 HSP90AA1 IFNG STAT1
12 11.62 IFNG IL10 IL17A
13 11.57 IFNG IL10 IL17RA
14
Show member pathways
11.56 DEFB4A HSP90AA1 IFNG IL17A IL17F IL17RA
15
Show member pathways
11.52 IL17A IL17F IL17RA IL17RC TRAF3IP2
16
Show member pathways
11.31 IFNG IL17A IL17F IL17RA STAT1

GO Terms for Candidiasis

Cellular components related to Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.28 APCS DEFB4A HSP90AA1 HTN3 IFNG IL10

Biological processes related to Candidiasis according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.91 AIRE DEFB4A IFNG IL10 IL17A
2 humoral immune response GO:0006959 9.67 AIRE IFNG TRAF3IP2
3 interleukin-12-mediated signaling pathway GO:0035722 9.65 IFNG IL10 STAT1
4 defense response to fungus GO:0050832 9.56 HTN3 IL17A IL17RA IL17RC
5 chaperone-mediated protein complex assembly GO:0051131 9.54 APCS HSP90AA1
6 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.52 IFNG STAT1
7 positive regulation of interleukin-6 secretion GO:2000778 9.5 IL17A IL17F IL17RC
8 granulocyte chemotaxis GO:0071621 9.46 IL17RA IL17RC
9 regulation of interleukin-6 biosynthetic process GO:0045408 9.43 CARD9 IL17F
10 fibroblast activation GO:0072537 9.4 IL17A IL17RA
11 regulation of interleukin-2 biosynthetic process GO:0045076 9.37 CARD9 IL17F
12 positive regulation of interleukin-23 production GO:0032747 9.33 IFNG IL17A IL17RA
13 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.26 IL17A IL17F IL17RA IL17RC
14 cellular response to interleukin-17 GO:0097398 8.92 IL17A IL17F IL17RA IL17RC

Molecular functions related to Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 IFNG IL10 IL17A IL17F
2 interleukin-17 receptor activity GO:0030368 8.62 IL17RA IL17RC

Sources for Candidiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....